Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.

about

Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.

Item

http://www.wikidata.org/entity/Q53201325

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Multi-institutional external v ...... ncorporating MGMT methylation.

@en

Multi-institutional external v ...... ncorporating MGMT methylation.

@nl

type

Item

label

Multi-institutional external v ...... ncorporating MGMT methylation.

@en

Multi-institutional external v ...... ncorporating MGMT methylation.

@nl

prefLabel

Multi-institutional external v ...... ncorporating MGMT methylation.

@en

Multi-institutional external v ...... ncorporating MGMT methylation.

@nl

P1476

Multi-institutional external v ...... ncorporating MGMT methylation.

@en

P2093

Haley Gittleman

http://www.w3.org/2001/XMLSchema#string

Jason K Molitoris

http://www.w3.org/2001/XMLSchema#string

Liam T Kane

http://www.w3.org/2001/XMLSchema#string

Minesh P Mehta

http://www.w3.org/2001/XMLSchema#string

Rajal A Patel

http://www.w3.org/2001/XMLSchema#string

Shahed N Badiyan

http://www.w3.org/2001/XMLSchema#string

Yuan James Rao

http://www.w3.org/2001/XMLSchema#string

P2860

IDH1 and IDH2 mutations in gliomas

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

The somatic genomic landscape of glioblastoma

Epidemiologic and molecular prognostic review of glioblastoma

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

A randomized trial of bevacizumab for newly diagnosed glioblastoma

Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

P2888

s11060-017-2529-2

P304

331-338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-017-2529-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P50

Søren M Bentzen

Jiayi Huang

Tim J Kruser

Jill S Barnholtz-Sloan

P577

2017-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28643151

http://www.w3.org/2001/XMLSchema#string